Molecular hydrogen attenuates cisplatin-induced nephrotoxicity by modulating β-hydroxybutyrate metabolism
Tian Y, Su H, Chen Y, Geng X, Zhang Y, Wang Y, Tang W, Fan W, Zhou J, Wei Y. · Molecular biology reports. 2025;52(1):751.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Metabolic and lipid health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
cells, cell, mice, tissues used to study metabolic and lipid health.
Preclinical study; group or assay counts reported in the full text include n=8.
Multiple article-specific time points; see the linked full methods.
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 30%, 10%, 20%, 21%, 5%, 0%, 20 µM.
Inhaled molecular H₂ at 30%; oxygen co-delivery is reported.
H₂-related quantities reported in the intervention passages: 30%, 10%, 20%, 21%, 5%, 0%, 20 µM. Values are not combined across different experimental arms.
Not reported in the full article — an absolute H₂ flow in mL/min could not be verified.
21% O₂ reported; total flow is absent, so O₂ flow in mL/min cannot be calculated.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “These pathological features were significantly ameliorated in mice pretreated with H_2, as evidenced by reduced structural damage and lower tubular injury scores (Fig. [1]B).” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. Funding or grant information is reported in the full article. The article declares no conflicts of interest.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 40705191 · DOI: 10.1007/s11033-025-10845-0
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10